Skip to main content
欧康医药 logo

欧康医药 — Investor Relations & Filings

Ticker · 920230 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 373 across all filing types
Latest filing 2025-04-16 Annual Report
Country CN China
Listing Beijing Stock Exchange 920230

About 欧康医药

https://www.okaypharm.com/

Oukang Pharmaceutical specializes in the research, development, and large-scale production of natural plant extracts, with a primary focus on citrus-derived flavonoids. The company’s core product portfolio includes high-purity ingredients such as Hesperidin, Diosmin, Methyl Hesperidin, and Neohesperidin Dihydrochalcone (NHDC). These products serve as essential raw materials for the global pharmaceutical, nutraceutical, food and beverage, and cosmetic sectors. Utilizing advanced extraction and purification technologies, the company maintains rigorous quality control standards to ensure compliance with international regulatory requirements. Its operations emphasize the industrialization of plant-based chemical derivatives to support diverse health and wellness applications.

Recent filings

Filing Released Lang Actions
2024年年度报告摘要
Annual Report Classification · 95% confidence The document is titled '年度报告摘要 2024' which translates to 'Annual Report Summary 2024'. It contains detailed financial data for the year 2024, including assets, net profit, earnings per share, and shareholder information. It also includes management assurances about the accuracy of the report and mentions an unqualified audit opinion from an accounting firm. The content covers company business overview, financial performance, shareholding structure, and other comprehensive annual report elements. The length is over 6000 characters, indicating it is not a mere announcement or summary notice but a substantive report. Therefore, this document fits the definition of an Annual Report (10-K). FY 2024
2025-04-16 Chinese
2025年度租赁办公场所暨关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a related party transaction for leasing office space in 2025 by Chengdu Oukang Pharmaceutical Co., Ltd. It details the transaction overview, parties involved, pricing policy, and approvals by the board and supervisory committee. It is not a financial report, earnings release, or management discussion. It is a regulatory announcement about a specific related party transaction, which fits best under the category of Regulatory Filings (RNS) as it does not fit other more specific categories like Capital/Financing Update or Board/Management Information. The document length is 2507 characters, and it is a full announcement, not a report publication notice or certification. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2025-04-16 Chinese
董事会关于独立董事独立性自查情况的专项报告
Regulatory Filings Classification · 95% confidence The document is a special report from the board of directors regarding the independence of the company's independent directors. It references regulatory guidelines about independent directors and provides a detailed assessment of their independence. The document is not an annual report, audit report, or financial statement, nor is it a voting result or a management change announcement. It is a regulatory compliance report related to governance but does not detail governance structure or compensation. Given its nature as a specialized report on director independence, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory compliance documents that do not fit other categories.
2025-04-16 Chinese
2024年度独立董事述职报告（赵宇霆）
Board/Management Information Classification · 95% confidence The document is titled as the "2024年度独立董事述职报告（赵宇霆）" which translates to "2024 Annual Independent Director's Work Report (Zhao Yuting)". It is a detailed report by an independent director about his duties, attendance, communications with audit committees and auditors, and other governance-related activities during the year 2024. The content focuses on the director's role, meetings attended, audit committee involvement, and protection of investor rights. It does not contain financial statements or earnings data, nor is it an announcement of voting results or a proxy statement. It is a management-related report focusing on board and governance activities, specifically the independent director's report on his duties and oversight. This fits best under Board/Management Information (MANG) as it relates to management and board-level disclosures about director activities and governance oversight. The document length is 3851 characters, which is relatively short but contains substantive content about the director's role and activities, not just an announcement or certification. Therefore, the classification is MANG with high confidence.
2025-04-16 Chinese
关于2025年度董事、监事及高级管理人员薪酬方案的公告
Remuneration Information Classification · 95% confidence The document is an announcement regarding the 2025 remuneration scheme for the company's directors, supervisors, and senior management. It details the salary standards, approval procedures, and related governance matters. It does not contain financial statements or performance data, nor is it a report or presentation. The content focuses on compensation policies and governance related to remuneration. This matches the definition of a Remuneration Information filing, which reports compensation details for top executives and directors. The document length is short and it is not a report publication announcement or certification. Therefore, the appropriate classification is Remuneration Information (DEF 14A).
2025-04-16 Chinese
申万宏源证券承销保荐有限责任公司关于成都欧康医药股份有限公司关联担保暨关联交易的核查意见
Regulatory Filings
2025-04-16 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.